Strauss G - Search Results

1

Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.

Poon MC, d'Oiron R, Hann I, Négrier C, de Lumley L, Thomas A, Karafoulidou A, Demers C, Street A, Huth-Kühne A, Petrini P, Fressinaud E, Morfini M, Tengborn L, Marquès-Verdier A, Musso R, Devecioglu O, Houston DS, Lethagen S, Van Geet C, von Depka M, Berger C, Beurrier P, Britton HA, Gerrits W, Guthner C, Kuhle S, Lorenzo JJ, Makris PE, Nohe N, Paugy P, Pautard B, Torchet MF, Trillot N, Vicariot M, Wilde J, Winter M, Chambost H, Ingerslev J, Peters M, Strauss G. Poon MC, et al. Among authors: strauss g. Semin Hematol. 2001 Oct;38(4 Suppl 12):21-5. doi: 10.1016/s0037-1963(01)90143-x. Semin Hematol. 2001. PMID: 11735106 Review.

2

A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.

Strauss GM, Lynch TJ, Elias AD, Jacobs C, Kwiatkowski DJ, Shulman LN, Carey RW, Grossbard ML, Jauss S, Sugarbaker DJ, et al. Strauss GM, et al. Semin Oncol. 1995 Aug;22(4 Suppl 9):70-4. Semin Oncol. 1995. PMID: 7544029 Clinical Trial.

3

Multimodality treatment of stage IIIA non-small-cell lung carcinoma: a critical review of the literature and strategies for future research.

Strauss GM, Langer MP, Elias AD, Skarin AT, Sugarbaker DJ. Strauss GM, et al. J Clin Oncol. 1992 May;10(5):829-38. doi: 10.1200/JCO.1992.10.5.829. J Clin Oncol. 1992. PMID: 1314892 Review.

4

Neoadjuvant and adjuvant therapy in the management of locally advanced non-small-cell lung cancer.

Jaklitsch MT, Strauss GM, Sugarbaker DJ. Jaklitsch MT, et al. Among authors: strauss gm. World J Surg. 1993 Nov-Dec;17(6):729-34. doi: 10.1007/BF01659082. World J Surg. 1993. PMID: 8109109 Review.

5

Advances in surgical staging and therapy of non-small-cell lung cancer.

Sugarbaker DJ, Strauss GM. Sugarbaker DJ, et al. Among authors: strauss gm. Semin Oncol. 1993 Apr;20(2):163-72. Semin Oncol. 1993. PMID: 8386855 Review.

6

Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.

Strauss GM, Lynch TJ, Elias AD, Jacobs C, Herbst R, Leong T, Lynch C, Kwiatkowski DJ, Carey RW, Grossbard ML, Skarin AT. Strauss GM, et al. Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-73-S12-80. Semin Oncol. 1997. PMID: 9331127 Clinical Trial.

7

Extent of surgery and survival in early lung carcinoma: implications for overdiagnosis in stage IA nonsmall cell lung carcinoma.

Sugarbaker DJ, Strauss GM. Sugarbaker DJ, et al. Among authors: strauss gm. Cancer. 2000 Dec 1;89(11 Suppl):2432-7. doi: 10.1002/1097-0142(20001201)89:11+<2432::aid-cncr17>3.3.co;2-1. Cancer. 2000. PMID: 11147621 Review.

8

Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.

Lynch TJ Jr, Kalish LA, Kass F, Strauss G, Elias A, Skarin A, Shulman L, Sugarbaker D, Frei E. Lynch TJ Jr, et al. Among authors: strauss g. Cancer. 1994 Feb 15;73(4):1171-6. doi: 10.1002/1097-0142(19940215)73:4<1171::aid-cncr2820730408>3.0.co;2-l. Cancer. 1994. PMID: 8313319 Clinical Trial.

9

Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer.

Lynch TJ Jr, Kass F, Kalish LA, Elias AD, Strauss G, Shulman LN, Sugarbaker DJ, Skarin A, Frei E 3rd. Lynch TJ Jr, et al. Among authors: strauss g. Cancer. 1993 May 15;71(10):2953-7. doi: 10.1002/1097-0142(19930515)71:10<2953::aid-cncr2820711011>3.0.co;2-j. Cancer. 1993. PMID: 8387871

10

Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC).

Elias AD, Skarin AT, Leong T, Mentzer S, Strauss G, Lynch T, Shulman L, Jacobs C, Abner A, Baldini EH, Frei E 3rd, Sugarbaker DJ. Elias AD, et al. Among authors: strauss g. Lung Cancer. 1997 May;17(1):147-61. doi: 10.1016/s0169-5002(97)00658-2. Lung Cancer. 1997. PMID: 9194034 Clinical Trial.

Continuous infusion cisplatin 25 mg/m2/day 1-5, 5-fluorouracil 800 mg/m2/day 2-5, and high-dose leukovorin 500 mg/m2/day 1-5 (PFL) given every 4 weeks achieved a 41% response rate in metastatic NSCLC (Lynch TJ, Kalish LA, Kass F, Strauss G, Elias A, Skarin A, Shulma …

Continuous infusion cisplatin 25 mg/m2/day 1-5, 5-fluorouracil 800 mg/m2/day 2-5, and high-dose leukovorin 500 mg/m2/day 1-5 (PFL) given eve …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

728 results

Search Page